TY - JOUR
T1 - Components necessary for high-quality lung cancer screening
T2 - American college of chest physicians and American thoracic society policy statement
AU - Mazzone, Peter
AU - Powell, Charles A.
AU - Arenberg, Douglas
AU - Bach, Peter
AU - Detterbeck, Frank
AU - Gould, Michael K.
AU - Jaklitsch, Michael T.
AU - Jett, James
AU - Naidich, David
AU - Vachani, Anil
AU - Wiener, Renda Soylemez
AU - Silvestri, Gerard
N1 - Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Mazzone has previously attended advisory panel meetings for Oncimmune and Varian. He has received research funding from Metabolomx and Integrated Diagnostics, paid to his institution. He directs the lung cancer screening program for the Cleveland Clinic. Dr Powell has previously served as a consultant for Pfizer Inc. Dr Arenberg is on the ACRIN DSMB for biomarker studies (voluntary academic position). He directs the lung cancer screening program for the University of Michigan Health System. Dr Bach is on the advisory boards for CMS and MEDCAC. He directs the Center for Health Policy and Outcomes at MSKCC. Dr Detterbeck has been a speaker for Lilly Oncology (lectures related to staging); on the DSMB for Olympus (endobronchial valve trial), and external grant administration board for Pfizer (paid to institution); attended advisory panel meetings for Covidien and Oncimmune; has received research funding to institution from Medela; and was vice-chair of the ACCP lung cancer guidelines 3rd edition. He is the Co-Director of the Yale lung cancer screening program. Dr Gould has received salary support from Evidera (formerly Archimedes, Inc) to help develop computer models of lung cancer screening. He is Director for Health Services Research and Implementation Science for Kaiser Permanente Southern California. Dr Jaklitsch served as co-chair of the AATS Lung Cancer Screening and Surveillance Task Force. Dr Jett is the principal investigator on lung cancer biomarker screening studies, and his institution has received grants to support his studies from Oncimmune, Inc and Metabolomx. He has served on the advisory board for Quest Diagnostics. Dr Naidich has participated in a Medical Advisory Board meeting sponsored by Seimens Medical Solutions and attended a meeting at the US Food and Drug Administration on behalf of Seimens Medical Solutions reviewing an upgrade to approval of a CAD to detect lung modules. Dr Vachani has received research funding from Integrated Diagnostics Inc, Janssen Research & Development, and Allegro Diagnostics. He has served on a scientific advisory board for Allegro Diagnostics. He is Co-Director of the University of Pennsylvania Lung Cancer Screening Program. Dr Wiener has received grant funding from the National Institutes of Health and US Department of Veterans Affairs paid to her institution. She is the Research Director for the lung cancer screening and pulmonary nodule evaluation clinic at Boston University School of Medicine. Dr Silvestri has received research support for Allegro and Integrated Diagnostics, Veran, and Olympus. He has received salary support from Archimedes to help develop computer models of lung cancer screening. He is director of the multidisciplinary thoracic oncology clinic at his institution.
Publisher Copyright:
© 2015 American College of Chest Physicians.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Lung cancer screening with a low-dose chest CT scan can result in more benefit than harm when performed in settings committed to developing and maintaining high-quality programs. This project aimed to identify the components of screening that should be a part of all lung cancer screening programs. To do so, committees with expertise in lung cancer screening were assembled by the Thoracic Oncology Network of the American College of Chest Physicians (CHEST) and the Thoracic Oncology Assembly of the American Thoracic Society (ATS). Lung cancer program components were derived from evidence-based reviews of lung cancer screening and supplemented by expert opinion. This statement was developed and modified based on iterative feedback of the committees. Nine essential components of a lung cancer screening program were identified. Within these components 21 Policy Statements were developed and translated into criteria that could be used to assess the qualification of a program as a screening facility. Two additional Policy Statements related to the need for multisociety governance of lung cancer screening were developed. High-quality lung cancer screening programs can be developed within the presented framework of nine essential program components outlined by our committees. The statement was developed, reviewed, and formally approved by the leadership of CHEST and the ATS. It was subsequently endorsed by the American Association of Throacic Surgery, American Cancer Society, and the American Society of Preventive Oncology.
AB - Lung cancer screening with a low-dose chest CT scan can result in more benefit than harm when performed in settings committed to developing and maintaining high-quality programs. This project aimed to identify the components of screening that should be a part of all lung cancer screening programs. To do so, committees with expertise in lung cancer screening were assembled by the Thoracic Oncology Network of the American College of Chest Physicians (CHEST) and the Thoracic Oncology Assembly of the American Thoracic Society (ATS). Lung cancer program components were derived from evidence-based reviews of lung cancer screening and supplemented by expert opinion. This statement was developed and modified based on iterative feedback of the committees. Nine essential components of a lung cancer screening program were identified. Within these components 21 Policy Statements were developed and translated into criteria that could be used to assess the qualification of a program as a screening facility. Two additional Policy Statements related to the need for multisociety governance of lung cancer screening were developed. High-quality lung cancer screening programs can be developed within the presented framework of nine essential program components outlined by our committees. The statement was developed, reviewed, and formally approved by the leadership of CHEST and the ATS. It was subsequently endorsed by the American Association of Throacic Surgery, American Cancer Society, and the American Society of Preventive Oncology.
UR - http://www.scopus.com/inward/record.url?scp=84927911832&partnerID=8YFLogxK
U2 - 10.1378/chest.14-2500
DO - 10.1378/chest.14-2500
M3 - Comment/debate
C2 - 25356819
AN - SCOPUS:84927911832
SN - 0012-3692
VL - 147
SP - 295
EP - 303
JO - Chest
JF - Chest
IS - 2
ER -